STOCK TITAN

Oculis Holding - OCS STOCK NEWS

Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.

Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.

Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.

Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.

Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reported that its lead product candidate OCS-01 eye drop met primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery, following a positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME). The company also enrolled the first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for the treatment of cystoid macular edema (CME). Oculis has cash and investments of $116.5 million, which is adequately funded to deliver on key business and clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
-
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced that its CEO and CFO will be presenting at upcoming investor conferences, including the Stifel 2023 Healthcare Conference and BTIG 3rd Annual Ophthalmology Day. The management team will also attend the Piper Sandler 35th Annual Healthcare Conference, offering one-on-one meetings for interested investors. Links to access company presentation and webcast for select events will be posted to Oculis’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
Rhea-AI Summary
Oculis Holding AG announced positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME). The results will be presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. OCS-01 is the first investigational eye drop for both front and back of the eye indications, with positive results in previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences clinical trial
Rhea-AI Summary
Oculis announces positive results from Phase 3 DIAMOND trial for DME
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
Rhea-AI Summary
Oculis Holding AG announces positive readout from Phase 3 DIAMOND trial of OCS-01 in patients with DME
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences clinical trial
-
Rhea-AI Summary
Oculis appoints Rebecca Weil as Chief Commercial Officer following positive clinical milestones on OCS-01 and NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
Rhea-AI Summary
Oculis Holding AG to present at upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
Rhea-AI Summary
Oculis achieved positive Phase 3 results for OCS-01 in diabetic macular edema and inflammation and pain following cataract surgery. Raised $146 million in gross proceeds. Enrolled first patient in LEOPARD trial for cystoid macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
-
Rhea-AI Summary
Oculis Holding AG has announced positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops. The trial demonstrated superior reduction in inflammation and pain compared to the vehicle following cataract surgery. OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Oculis Holding

Nasdaq:OCS

OCS Rankings

OCS Stock Data

864.96M
43.64M
7.04%
31.04%
0.05%
Biotechnology
Healthcare
Link
Switzerland
Zug